<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ijerph-17-01395-t001" orientation="portrait" position="float">
 <object-id pub-id-type="pii">ijerph-17-01395-t001_Table 1</object-id>
 <label>Table 1</label>
 <caption>
  <p>Characteristics of included studies on public health outcomes due to AMR.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author by Disease</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Year</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Site</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sample Size</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Design/Method</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Outcome</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Quality Assessment</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Warsame et al. [
     <xref rid="B14-ijerph-17-01395" ref-type="bibr">14</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1982–1988</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Somalia</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">109</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The emergence of chloroquine resistance, accelerated by high drug pressure, low herd immunity and favourable meteorological conditions were identified as major causes of the epidemic of falciparum malaria in Balcad, Somalia.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sharma et al. [
     <xref rid="B15-ijerph-17-01395" ref-type="bibr">15</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1994</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In 1994, there was a falciparum malaria epidemic in Rajasthan, India, with many deaths, and most of the parasite isolates (95%) were resistant to chloroquine.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Knight et al. [
     <xref rid="B16-ijerph-17-01395" ref-type="bibr">16</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1982–1988, 1991–2001</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">South Africa</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">600000</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ecological study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The relative risk for malaria infection after the level of drug resistance reached 10% was 4.5 (95% CI: 4.0–5.2) in the chloroquine period and 5.9 (95% CI: 5.7–6.1) in the sulfadoxine-pyrimethamine period.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MODERATE</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Slater et al. [
     <xref rid="B17-ijerph-17-01395" ref-type="bibr">17</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016–2020</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Africa</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An individual-based malaria transmission model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Artemisinin and partner drug resistance at levels similar to those observed in Oddar Meanchey province in Cambodia could result in an additional 78 million cases over a 5 year period, a 7% increase in cases compared to a scenario with no resistance.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tuberculosis</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reves et al. [
     <xref rid="B18-ijerph-17-01395" ref-type="bibr">18</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1976</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective investigation</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An outbreak of tuberculosis in 1976 was caused by mycobacteria resistant to isoniazid (INH), streptomycin (SM), and para-aminosalicylic acid (PAS).</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ussery et al. [
     <xref rid="B19-ijerph-17-01395" ref-type="bibr">19</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A trend between TST conversion and participation in autopsies on persons with MDR-TB was observed.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coronado et al. [
     <xref rid="B20-ijerph-17-01395" ref-type="bibr">20</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1990–1991</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">From January 1990 to December 1991, 16 patients with multidrug-resistant tuberculosis (MDR-TB) were caused by nosocomial transmission of MDR-TB resistant to isoniazid, rifampin, and streptomycin.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Friedman et al. [
     <xref rid="B21-ijerph-17-01395" ref-type="bibr">21</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1995</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">167</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Forty-three (34%) of 127 drug-susceptible isolates and 19 (79%) of 24 multidrug-resistant isolates had RFLP patterns representing possible recent exogenous infection.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">US CDC. [
     <xref rid="B22-ijerph-17-01395" ref-type="bibr">22</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1990–1991</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NR</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">During 1990 and 1991, outbreaks of multidrug-resistant tuberculosis (MDR-TB) in four hospitals (one in Miami and three in New York City) were due to nosocomial transmission among HIV-infected persons.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivin et al. [
     <xref rid="B23-ijerph-17-01395" ref-type="bibr">23</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1998</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cross-sectional study</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nosocomial transmission appeared to account for an increase in cases of multidrug-resistant tuberculosis (MDRTB) at a large urban facility where a prior nosocomial outbreak of MDRTB had occurred.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Powell et al. [
     <xref rid="B24-ijerph-17-01395" ref-type="bibr">24</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008–2015</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective investigation</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Of 110 outbreak cases in Georgia, 86 (78%) were culture confirmed and isoniazid resistant.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">STRONG</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mehra et al. [
     <xref rid="B25-ijerph-17-01395" ref-type="bibr">25</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010–2050</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dynamic state transition model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In China, by 2050, incidence, prevalence and mortality of MDR-TB will increase by respectively 60%, 48% and 35%, which attributed to inappropriate treatment, leading to high transmission of infection and increased LTBI prevalence.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sharma et al. [
     <xref rid="B26-ijerph-17-01395" ref-type="bibr">26</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000–2040</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">India, Philippines, Russia and South Africa</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A compartmental model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The model forecasted the percentage of MDR tuberculosis among incident cases of tuberculosis to increase, reaching 12.4% (95% prediction interval 9.4–16.2) in India, 8·9% (4.5–11.7) in the Philippines, 32.5% (27.0–35.8) in Russia, and 5·7% (3.0–7.6) in South Africa in 2040. It also predicted the percentage of XDR tuberculosis among incident MDR tuberculosis to increase, reaching 8·9% (95% prediction interval 5.1–12.9) in India, 9·0% (4.0–14.7) in the Philippines, 9·0% (4.8–14.2) in Russia, and 8·5% (2.5–14.7) in South Africa in 2040.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blower et al. [
     <xref rid="B27-ijerph-17-01395" ref-type="bibr">27</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996–2005</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A mathematical model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The epidemic of resistance is being generated mainly by the conversion of drug-sensitive cases to drug-resistant cases, and not by the transmission of resistant strains.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Smith et al. [
     <xref rid="B28-ijerph-17-01395" ref-type="bibr">28</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008–2013</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A biologically complex multistrain network model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60% of the currently circulating ARV-resistant strains in San Francisco are capable of causing self-sustaining epidemics, because each individual infected with one of these strains can cause, on average, more than one new resistant infection.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phillips et al. [
     <xref rid="B29-ijerph-17-01395" ref-type="bibr">29</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016–2030</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sub-Saharan Africa</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV Synthesis Model</td>
    <td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In a situation in which current levels of pretreatment HIVDR are over 10% (mean, 15%), 16% of AIDS deaths (890 000 deaths), 9% of new infections (450 000), and 8% ($6.5 billion) of ART program costs in SSA in 2016–2030 will be attributable to HIVDR.</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEAK</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>NR, not reported.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
